A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis

Exclusion Criteria

• •Have been treated with disease-modifying antirheumatic drugs (DMARDs)/systemic immunosuppressives other than MTX.
• •Have received approved or investigational biological or targeted synthetic DMARD therapies for RA less than 6 months prior to screening.
• •Have a history of toxicity, non-tolerance, primary non-response or inadequate response to a biological therapy, or targeted synthetic DMARDs, for RA.
• •Have received prior therapy blocking the interleukin-6 (IL-6) pathway, at any time.
• •Others as defined in the protocol